During the conference, Dr Benedikt Westphalen, a medical oncologist at the University Hospital, LMU in Munich, Germany, addressed the question of whether both irinotecan and oxaliplatin are necessary in the first-line treatment for treatment-naïve metastatic pancreatic cancer. Additionally, the study aimed to determine if these agents could be administered sequentially. Dr Westphalen presented the efficacy and safety outcomes of the FOOTPATH study, an open-label phase-2 trial comparing different treatment regimens in this patient population.
The FOOTPATH study compared the efficacy and safety of liposomal irinotecan + 5-FU and folinic acid (NAPOLI regimen) versus sequential NAPOLI and mFOLFOX6 (combination of 5-FU, leucovorin, and oxaliplatin) versus the standard regimen of gemcitabine/nab-paclitaxel. The study sought to establish the optimal treatment approach for treatment-naïve metastatic pancreatic cancer patients.
With the educational support of:
